DIOS 203
Alternative Names: DIOS-203Latest Information Update: 02 Aug 2021
Price :
$50 *
At a glance
- Originator University of Bonn
- Developer DiosCURE Therapeutics; University of Bonn
- Class Antivirals; Immunoglobulin fragments; Single-domain antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 28 Jul 2021 DiosCURE in-licenses additional intellectual property related to DIOS 203 from University of Bonn and Scripps Research Institute for COVID-2019 infections
- 12 Jan 2021 DioCURE Therapeutics plans a phase I trial in COVID-2019 infections in 2021 (Parenteral)
- 12 Jan 2021 DiosCURE in-licenses DIOS 203 from University of Bonn for COVID-2019 infections